ALX Oncology Holdings Inc. Share Price & Technical Analysis
ALXO · $1.94 (-2.02%)
Healthcare / Biotechnology
$1.94
-2.02%
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaborat…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
18% return in May, -9% avg return in past 3 year May month.
81% return in 2026, 4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 55% | 24% | 0% | -15% | 18% | – | – | – | – | – | – | – | 81% |
| 25 | -12% | -21% | -45% | -17% | 0% | -20% | 50% | 100% | 64% | -17% | -12% | -15% | 54% |
| 24 | -2% | 1% | -24% | 52% | -38% | -44% | -17% | -28% | -22% | -22% | 7% | 13% | -124% |
| 23 | -17% | -30% | -33% | 28% | 10% | 12% | -19% | -30% | 9% | 50% | 8% | 91% | 81% |
| 22 | -27% | 12% | -3% | -25% | -39% | 4% | 20% | 31% | -26% | 23% | -10% | 2% | -38% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Uptrend · Uptrend
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$286.48M
P/E ratio
—
52W high
$2.66
52W low
$0.40
Volume
12,88,767
Beta
0.41
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is ALX Oncology Holdings Inc. share price today?
- ALX Oncology Holdings Inc. (ALXO) last traded around $1.94 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALXO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALXO. Download the app for real-time alerts.
- How can I analyze ALX Oncology Holdings Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.